RAPP (Rapport Therapeutics) Common Stock : $0.04 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Common Stock?

Rapport Therapeutics's quarterly common stock stayed the same from Jun. 2024 ($0.04 Mil) to Sep. 2024 ($0.04 Mil) but then increased from Sep. 2024 ($0.04 Mil) to Dec. 2024 ($0.04 Mil).

Rapport Therapeutics's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.04 Mil).

Rapport Therapeutics Common Stock Historical Data

The historical data trend for Rapport Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Common Stock Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Common Stock

0.04

Rapport Therapeutics Quarterly Data
	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial			-	-	0.04	0.04	0.04

Rapport Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.